Table 1.

Open-label, dose-response study designa

HWC vaccine inoculumLTR192G dose (μg)H. pylori statusNo. of subjects
2.5 × 106 25Uninfected3
2.5 × 106 25Infected3
2.5 × 108 25Uninfected4
2.5 × 108 25Infected3
2.5 × 1010 25Uninfected10
  • a For the purpose of characterizing the dose response, the eight H. pylori-infected subjects who received 2.5 × 1010 inactivated HWC vaccine plus 25 μg of LTR192G adjuvant as part of the randomized safety and immunogenicity study (Table 2) are also included in the analysis of this portion of the study.